Previous close | 1,043.50 |
Open | 1,015.50 |
Bid | 994.40 x 0 |
Ask | 1,044.00 x 0 |
Day's range | 991.00 - 1,016.00 |
52-week range | 887.00 - 1,316.75 |
Volume | |
Avg. volume | 3,499,129 |
Market cap | 9.124B |
Beta (5Y monthly) | 0.51 |
PE ratio (TTM) | 41.32 |
EPS (TTM) | 0.24 |
Earnings date | 27 Feb 2024 |
Forward dividend & yield | 0.30 (3.05%) |
Ex-dividend date | 28 Mar 2024 |
1y target est | 12.89 |
Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces it has been named the Preferred Sports Medicine Technology Partner of UFC – the world’s premier mixed martial arts organization and one of the foremost global brands in all of sports. Under the terms of the multi-year partnership, Smith+Nephew will activate its brand through UFC’s immense global presence to promote the repair, regeneration and recovery of Sports Medicine injuries through advanced technologies
When it comes to investing, there are some useful financial metrics that can warn us when a business is potentially in...
Shareholders might have noticed that Smith & Nephew plc ( LON:SN. ) filed its annual result this time last week. The...